Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) said its SHR-4375 Injection has received orphan drug designation from the U.S. Food and Drug Administration for treating pancreatic cancer.
The designation will provide the company with opportunities to receive U.S. policy support in the areas of product development, registration and commercialization, according to a Monday filing with the Shanghai bourse.